Tenalisib not checked

Rhizen Pharmaceuticals SA · RP6530

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
7 in total
Targets
 

What this is

How it works
Blocks PI3K, an enzyme that passes growth signals inside cells. Mostly used against cancer.-lisib: PI3K inhibitors WHO name stem
Tested for
Triple Negative Breast Cancer (TNBC)
Main trialPhase 2
“This is a Phase II, open-label, single-arm, study, designed to evaluate the efficacy and safety of tenalisib in patients with metastatic TNBC, who have received at least one but not more than 3 prior therapies in a metastatic setting.”In the company’s words, NCT06189209 on ClinicalTrials.gov
Other names
RP6530

Other drugs for Triple Negative Breast Cancer (TNBC)

All 151 drugs for Triple Negative Breast Cancer (TNBC)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials7

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 31 Dec 2026 Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
Phase 2Completed 16 Jun 2020 Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)
Phase 2Completed 2 Oct 2020 Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Phase 2Completed 31 Mar 2023 Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer
Phase 2Withdrawn Dec 2026 Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL
Phase 1/2Completed 14 May 2021 Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma
Phase 1/2Completed 25 Mar 2023 Compassionate Use Study of Tenalisib (RP6530)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Tenalisib

Following is part of Solo: you see every change to Tenalisib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in